Imurek (Azathioprine)

Azathioprine is converted to 6‑mercaptopurine inside cells, where it blocks the synthesis of purine nucleotides. This inhibition reduces DNA, RNA and protein production in rapidly dividing lymphocytes, thereby dampening the immune response and limiting tissue inflammation.

The specific dose of Imurek is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and response to therapy. Dosage adjustments are made during treatment to achieve the desired therapeutic effect while minimizing toxicity.

The safety of azathioprine in pregnancy and lactation is not fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Imurek product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with alternatives such as mycophenolate mofetil or cyclosporine, azathioprine offers a distinct mechanism by inhibiting purine synthesis. It is often chosen for its oral formulation and long‑term safety profile, though individual response and side‑effect risk vary, making clinician‑guided selection essential.

Imurek should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Imurek is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact schedule—once daily or divided doses—depends on the prescribing physician’s instructions.

Serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity, opportunistic infections, pancreatitis, and an increased long‑term risk of certain malignancies. Patients should be monitored regularly for blood count and liver function abnormalities.

Imurek is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites, those with severe bone‑marrow failure, active uncontrolled infections, or pregnant women unless the benefits outweigh the risks. It should also be used with caution in individuals with significant hepatic or renal impairment.